Testing how a statin may change immune markers in prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether taking simvastatin can change “immune regulation” markers in men with intermediate- to high-risk localized prostate cancer. It also looks at whether this could help lower the risk of cancer coming back after planned prostate surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re a man with prostate cancer confirmed by biopsy, and your case is intermediate- or high-risk for recurrence (based on specific stage, PSA, or Gleason score).
- You plan to have a prostatectomy (prostate removal surgery).
- You can sign consent and complete the study visits and tests.
- You are not currently taking statins or other cholesterol-lowering medicines like fibrates, bile acid blockers, or niacin.
- You have no known prostate cancer spread to other parts of the body (no metastases).
- You do not have major medication or health issues that make simvastatin unsafe (such as certain drug interactions, very low LDL cholesterol, diabetes or diabetes medicines, prior heart attack or stroke, significant liver or kidney disease, or severe muscle problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
This trial tests whether a structured exercise program, along with the cholesterol medicine atorvastatin, can improve outcomes in people with metastatic prostate, breast, ovarian, or kidney cancer. It may help by reducing inflammation and supporting physical function during cancer treatment.
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
This study tests whether statins, a common cholesterol-lowering medication, can improve erectile function and hormone levels in men at high risk for heart problems. It aims to see if these benefits exist beyond just lowering cholesterol.
This trial tests whether adding a statin to progesterone therapy helps young women with early endometrial cancer or atypical endometrial hyperplasia who want to preserve their fertility. It aims to find a better treatment option for those who may not respond well to progesterone alone.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.